Honda Racing Corporation (HRC) announced that its factory team(1) “Team HRC” will race the CR ELECTRIC PROTO electric motocrosser in the FIM(2) E-Xplorer World Cup, an international electric all-terrain motorcycle racing series.
Team HRC will be represented by 2024 Dakar Rally rider Tosha Schareina (Spain, age 28) and Italian WMX champion Francesca Nocera (Italy, age 30).
Honda is committed to the electrification of motorcycles as the mainstay of its future environmental strategy, aiming to achieve carbon neutrality through all Honda-related products and corporate activities in 2050, and in all motorcycle products in the 2040s. In motorsports last year, Honda made a spot entry in the All Japan Motocross Championship (JMX) with the CR ELECTRIC PROTO, and it will continue to strengthen its technology by competing in new electric motorcycle races.
Koji Watanabe, President of Honda Racing Corporation
“As Honda’s commitment to carbon neutrality grows in importance, HRC has decided to enter the FIM E-Xplorer World Cup, a new category of electric off-road motorcycle racing in motorcycle motorsports. By taking on the challenge of a new electric motorcycle racing series, HRC will hone its technology in a real-world setting, accumulate know-how and knowledge, and further accelerate development of human resources. We hope you will look forward to Honda’s efforts.”
Francesca Nocera Birth date: October 23, 1993 (age 30)Birthplace: Italy Career highlights: 2015 Italian WMX Championship: Winner 2016 Italian WMX Championship: Winner 2017 Italian WMX Championship: 2nd 2019 Italian WMX Championship: Winner 2023 FIM Women’s Enduro World Championship: 3rd
E-Xplorer
The FIM E-Xplorer World Cup is a world series for electric off-road motorcycles that began in 2023, with mixed teams of men and women competing. This season’s competition will consist of a preliminary round for men and women, followed by three-heat races to determine the first to third place teams in a competitive format. Races will be held on special courses of partially dirt and partially paved asphalt surfaces. In the first year, Sandra Gomez and Jorge Zaragoza of the Japanese team Team MIE won the championship.For the second year, the series will be held in Asia for the first time, with the opening round to be held at the Expo’70 Commemorative Park‘s Festival Square in Suita City, Osaka Prefecture, on February 16 and 17. Subsequent rounds will be held in Norway, France, Switzerland, and India.
(1) Factory team: operated by manufacturer. Honda factory teams operated by Honda Racing Corporation (HRC) (2) FIM: Fédération Internationale de Motocyclisme
For more details, visit FIM E-Xplorer World Cup’s official website:(https:// www.fimexplorer.com/)
A prominent player in the betting software provider industry has announced its entrance into the market with the launch of BookieHelper.com. This new platform aims to revolutionize how online bookies operate by offering personalized and professional assistance.
Led by a private investor with over 27 years of experience in Costa Rica’s offshore sportsbook scene, BookieHelper.com provides concierge-style support and scalable solutions for betting operators. The concept for the platform was born out of the founder’s observation of a gap in the market for personalized support.
The online sports sector has witnessed remarkable growth in recent years, driven by the surge in online betting. According to a report by ResearchAndMarkets, the global online sports betting market was valued at $24.4 billion in 2020 and is projected to reach $155.4 billion by 2028, with a notable CAGR of 28.3% during the forecast period.
With a growing demand for quality sports betting software solutions tailored to the needs of specific agents, BookieHelper offers a wide range of highly-customized services, including quick player setup and management of custom limits. It also provides turnkey solutions for bookies, complete with custom website design options. Moreover, they support seamless integration with third-party software, enabling easy adoption of payment processing solutions and API integration.
The platform boasts an impressive array of products, including pre-game sports betting markets, dynamic live betting providers, virtual casinos, live dealer casino solutions, premium racebook software, and props builder software. And their flexible pricing structure opens doors for small entrepreneurs who aspire to start their own bookmaking enterprises.
BookieHelper also offers call center services in English, Spanish, and Chinese. They also accept several payment methods, including cryptocurrencies, allowing customers to make payments safely and securely without compromising sensitive financial information.
“Our mission at BookieHelper.com is to provide professional support that exceeds our customers’ expectations. We believe in going the extra mile to ensure their success. We are dedicated to revolutionizing the betting software industry by offering scalable solutions and a rental model that empowers small entrepreneurs to thrive. Our customers can expect a partnership built on trust, innovation, and unwavering support.” – JC Hernandez, Founder.
With highly-customized services, scalable solutions, and a rental model that empowers small entrepreneurs, BookieHelper.com meets the evolving needs of sports and casino betting operators. Join BookieHelper.com on this exciting journey as they redefine the future of betting software.
Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration.
BB-1701 is an ADC that is composed of Eisai’s in-house developed anticancer agent eribulin, and anti-HER2 antibody using a linker, and is expected to have anti-tumor effects on breast, lung and other solid tumors that express HER2. The linker-payload, which uses eribulin as a payload, is a proprietary technology platform developed by Eisai’s U.S. research base Exton Site, and Eisai is investigating the possibilities of using this platform to link to various antibodies. Under a license agreement signed by the two companies in 2018, Eisai has granted BlissBio global exclusive development rights for several ADCs to use eribulin as the payload. Based on the status of the Phase I/II clinical trials of BB-1701 currently being conducted by BlissBio, the both companies have decided to co-develop this drug.
Under the terms of the joint development agreement, Eisai will make upfront and development milestone payments to BlissBio, conduct a Phase II clinical trial in breast cancer, and obtain option rights to develop and commercialize BB-1701 globally, excluding Greater China (China, Hong Kong, Macau, Taiwan). If Eisai exercises the option rights, an additional upfront payment will be made to BlissBio, as well as development and regulatory milestone payments, sales milestone payments and a certain amount of royalties on sales revenue of BB-1701 after the launch. If all development, regulatory and sales milestones are achieved, up to a total of $2 billion USD will be paid.
“BB-1701 is characterized by its payload of eribulin, which is a product of our modern synthetic organic chemistry that has already made contributions to patients with breast cancer and soft tissue sarcoma,” said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. “Our collaboration with BlissBio will accelerate the development of BB-1701 with the goal of bringing a new treatment option to patients globally.”
About Bliss Biopharmaceuticals (Hangzhou) Co., Ltd.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”), is a clinical-stage biotech company dedicated on discovery, development and commercialization of anti-tumor biotherapeutics, founded by pharmaceutical veterans in 2017 in Hangzhou, Zhejiang province. BlissBio has established a unique and patented technical platform, a rich ADC-focusing pipeline, and GMP manufacture capability that could support antibody and ADC production for both clinical development and early commercialization. BlissBio has been nominated as a national high-tech biopharmaceutical enterprise in China. With “Together, We Improve Human Health” as the core value, through international and domestic collaborations, BlissBio will continue to focus on innovative drugs to address unmet medical needs.
For more information, please visit https://www.blissbiopharma.com.
About BB-1701 (development code)
BB-1701 is an ADC that is composed of Eisai’s in-house developed anticancer agent eribulin, and anti-HER2 antibody using a linker, and is expected to have anti-tumor effects on breast, lung and other solid tumors that express HER2 through multiplex mechanisms like direct cytotoxicity (including immunogenic cell death), a bystander effect* and immune response-induced cell death. BlissBio is currently conducting Phase I/II clinical trials in the U.S. and China for HER2-expressing solid tumors.
*Bystander effect: When the anticancer agent and antibody parts of an ADC are separated inside a targeted antigen-positive cancer cell, the released anticancer agent also affects neighboring antigen-negative cancer cells and the component cells of the cancer microenvironment.
For more information, visit www.eisai.com/news/2023/news202330.html.
Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120
Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name “Tazverik Tablets 200 mg”, “tazemetostat”) based on “Patient-Proposed Healthcare Services” system. This clinical research will be conducted by the National Cancer Center Hospital.
The “Patient-Proposed Healthcare Services” system is a system under which medical treatment using unapproved drugs not covered by insurance is applied for to the government based on the patient’s request, and is conducted as a clinical trial to confirm safety and efficacy. Under the terms of the agreement, Eisai will provide tazemetostat free of charge to the National Cancer Center Hospital as the drug to be used in “A clinical trial of Tazemetostat for pediatric and AYA* patients with malignant tumors which have no standard of care or and which is refractory to standard of care: Patients-Proposed Healthcare Service” to be conducted by the hospital under this program.
Researched and developed by Eisai and Epizyme, Inc.,** an Ipsen (Headquarters: France) company, tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2. It is one of the histone methyltransferases in the epigenetics-related protein group, and is thought to regulate the expression of cancer-related genes and suppress the growth of cancer cells by specifically targeting EZH2, which contributes to the cancer growth process.1 Eisai holds the rights for development and commercialization of tazemetostat in Japan, where it was approved for the indication of “relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)” in 2021, and manufactures and distributes the product.
Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai is committed to expanding the potential clinical benefits of tazemetostat for cancer treatment, as it seeks to contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families and healthcare professionals.
*AYA (Adolescent & Young Adult): Patients between the ages of 15 and 39. **Acquired by Ipsen in 2022
Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120
For more information, visit www.eisai.com/news/2023/news202326.html.
B.Duck, a global character IP is entering Web3 with its first metaverse partnership with GigaSpace, working alongside MADworld to establish a Web3 blueprint for brands and IPs in the metaverse. Created by the Hong Kong-listed company Semk Holdings International Limited (2250.HK), B.Duck joins the initiative “Project Spaceport” by acquiring land NFTs in the GigaSpace and will build experiences to bring joy, positivity, and fun to its 10+ million fans around the world.
Brought into the digital world by the NFT platform MADworld, B.Duck has already launched a 3D NFT collection. NFT owners can soon travel through GigaSpace and spread positivity to every corner of the virtual space.
Project Spaceport & Web3
Project Spaceport will be a cultural space district. Brands will be able to create their own virtual space when the Metaverse launches. B.Duck has already cemented its web3 presence permanently on the “Map of the Galaxy” at GigaSpace.
MADworld, an NFT platform backed by Animoca brands, has also committed to building Project Spaceport in the GigaSpace.
When the GigaSpace metaverse launches, B.Duck will help build the Museum of Brands, which will be an innovative way for brands to showcase their products, vision, and mission. Another exciting feature is branded avatars – fans will be able to travel in the GigaSpace with a B.Duck avatar.
“We’re motivated by inspiring our fans the love for travel and bringing them joy and positivity. The metaverse is how we will experience Web3, and GigaSpace allows us to create innovative experiences for our fans,” said Mr. Eddie Hui, the founder of B.Duck.
“B.Duck entering Web3 is prominent in establishing a foundation for digital creatives for brands and IPs. We’re thrilled to be a part of the journey to offer tools for brands to express themselves in the metaverse,” said M, co-founder of GigaSpace.
About B.Duck
Designed by Eddie Hui in 2005, B.Duck was originally a gift for his children. B.Duck is the largest domestic character IP in China in terms of licensing revenue in 2021. With strong in-house artistic design capabilities, SEMK has developed and nurtured a proprietary portfolio of approximately 26 self-created characters created under the motto of “Be Playful”. As of 31 December 2021, B.Duck family characters had recorded in aggregate more than 10.5 million subscriptions or follows by B.Duck fans on various e-commerce platforms and social networking platforms, within aggregate, over 740 million views of various types of content in relation to the elements of B.Duck family characters.
About GigaSpace
GigaSpace is a blockchain-based virtual space metaverse where users can purchase land NFTs to create content and explore worlds. It offers a platform to drive the adoption of Web3 by helping brands and partners build their presence in the metaverse.
Contact
